Baillie Gifford & CO Precision Biosciences Inc Transaction History

Baillie Gifford & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$0.7 - $1.41 $498 - $1,003	-712 Reduced 1.16%	60,740 $45,000
Q3 2022 Oct 27, 2022	BUY	$1.22 - $40.8 $3,222 - $107,752	2,641 Added 4.49%	61,452 $80,000
Q2 2022 Aug 08, 2022	SELL	$1.15 - $3.34 $3,167 - $9,198	-2,754 Reduced 4.47%	58,811 $94,000
Q1 2022 May 05, 2022	BUY	$2.96 - $7.76 $31,050 - $81,402	10,490 Added 20.54%	61,565 $190,000
Q4 2021 Jan 20, 2022	BUY	$7.4 - $11.66 $367,091 - $578,417	49,607 Added 3379.22%	51,075 $378,000
Q3 2021 Oct 19, 2021	BUY	$9.18 - $14.15 $5,893 - $9,084	642 Added 77.72%	1,468 $17,000
Q2 2021 Aug 02, 2021	BUY	$8.07 - $12.52 $6,665 - $10,341	826 New	826 $10,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $554M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.